Key Takeaways & Executive Findings
- •• Elevated body mass index is an independent risk factor for delayed early renal function recovery and prolonged hospital stay after kidney transplantation. • Each 1 kg/m² increase in body mass index is associated with a 38 μmol/L rise in postoperative day 1 creatinine and a 32 mL reduction in urine volume. • Obese recipients (BMI ≥ 28 kg/m²) had significantly higher age, lower living donor proportion, and worse early postoperative outcomes. • Individualized perioperative management, including enhanced monitoring and tailored immunosuppression, is recommended for obese kidney transplant recipients.
Abstract
BACKGROUND: The proportion of obesity in the Chinese population has increased year by year, but its impact on early renal function recovery after kidney transplantation has not been systematically elucidated, and localized research is urgently needed to provide evidence-based basis. OBJECTIVE: To investigate the effect of different body mass indexes on early renal function recovery in renal transplant recipients after surgery, to analyze the association between body mass index and postoperative creatinine, urine volume and hospital stay, and to propose clinical recommendations for individualized management. METHODS: The clinical data of 495 renal transplant recipients in the Second Xiangya Hospital of Central South University from 2019 to 2020 were retrospectively analyzed. According to the Chinese obesity standard, they were divided into a lean group (body mass index < 18.5 kg/m2, n=78), a normal group (18.5 ≤ body mass index < 24 kg/m2, n=273), an overweight group (24 kg/m2 ≤ body mass index < 28 kg/m2, n=119), and an obese group (body mass index ≥ 28 kg/m2, n=25). The baseline characteristics, postoperative creatinine, urine volume, and hospital stay were compared among the groups. Multivariate regression analysis was used to analyze the independent effect of body mass index on postoperative recovery. RESULTS AND CONCLUSION: (1) The age of the obese group was significantly higher than that of other groups (P < 0.001), the proportion of living donors (0%) was the lowest (P=0.015), the creatinine level on postoperative day 1 and hospital stay were the highest (P < 0.001), and urine volume was the lowest (P < 0.001); (2) Multivariate regression showed that for each 1 kg/m2 increase in body mass index, creatinine on postoperative day 1 increased by 38 μmol/L (β=0.38, P < 0.001), and urine volume decreased by 32 mL (β=-0.41, P < 0.001); (3) It is suggested that elevated body mass index is an independent risk factor for slow early renal function recovery and prolonged hospital stay after kidney transplantation; based on the Chinese obesity standard (body mass index ≥ 28 kg/m2), it is recommended to strengthen perioperative monitoring, optimize immunosuppressive regimens, and formulate individualized fluid management strategies for obese recipients to improve prognosis. This study can provide evidence-based basis for localized body mass index stratified management.
1. Introduction
Kidney transplantation is the best treatment option for patients with end-stage renal disease, and the quality of early postoperative renal function recovery directly affects graft survival and long-term patient prognosis [1-2]. Among the multiple factors influencing transplant outcomes, the clinical significance of recipient body mass index has attracted increasing attention in recent years. The World Health Organization defines obesity as a body mass index ≥ 30 kg/m² [3], but metabolic abnormalities in Asian populations often occur at lower body mass index levels. In China, a body mass index ≥ 28 kg/m² is used as the diagnostic criterion for obesity [4-5]. This population specificity suggests the need for a localized assessment system.
Existing studies have shown that obesity may affect kidney transplant prognosis through multiple mechanisms: inflammatory factors released by adipose tissue exacerbate ischemia-reperfusion injury [6-8], increased intra-abdominal pressure leads to insufficient graft perfusion [9-10], and insulin resistance increases the risk of immunosuppressant toxicity [11-13]. However, quantitative studies on the impact of body mass index on early postoperative recovery indicators remain controversial: LIESE et al. [14] showed in a study of 384 recipients that body mass index ≥ 35 kg/m² was an independent risk factor for delayed graft function and graft survival; whereas ORLIC et al. [15] found no significant effect of body mass index on early renal function. Notably, these studies mostly focused on Western populations and had small sample sizes, lacking systematic analysis of the Chinese kidney transplant population.
Existing domestic literature mostly focuses on the association between body mass index and long-term complications, and systematic research on the immediate postoperative recovery phase (such as creatinine decline rate, urine output recovery, and hospital stay) also has significant limitations [16-17]. Delayed early renal function recovery has been proven to be an independent predictor of acute rejection and graft loss [18-19]. Furthermore, current clinical guidelines have not yet formed standardized protocols for perioperative management of obese patients [20-21], especially individualized intervention strategies based on Chinese body mass index stratification that urgently need improvement [22-23]. Based on this, this study retrospectively analyzed 495 kidney transplant cases, stratified by body mass index according to Chinese obesity standards, and focused on exploring the quantitative association between different body mass index levels and early postoperative renal function recovery indicators (serum creatinine, urine output) and healthcare resource consumption (hospital stay), aiming to provide evidence-based basis for perioperative fluid management, immunosuppressive regimen adjustment, and complication prevention in obese recipients. The results will help establish a risk prediction model based on body mass index stratification and promote the development of precise perioperative management strategies.
Loading authentic research manuscript (Pages 1–5)...
ZHONG Xiaoping, CHEN Dan, XIE Nianhua (2026). Correlation between body mass index and early recovery outcomes after kidney transplantation. Chinese Journal of Tissue Engineering Research. https://doi.org/10.12307/2026.21494
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the main finding of this study?
The study found that elevated body mass index is an independent risk factor for slow early renal function recovery and prolonged hospital stay after kidney transplantation. Specifically, each 1 kg/m² increase in body mass index was associated with a 38 μmol/L increase in postoperative day 1 creatinine and a 32 mL decrease in urine output.
How was obesity defined in this study?
Obesity was defined according to the Chinese obesity standard as a body mass index ≥ 28 kg/m². The study also categorized recipients into lean (<18.5 kg/m²), normal (18.5-23.9 kg/m²), overweight (24-27.9 kg/m²), and obese (≥28 kg/m²) groups.
What are the clinical implications of this study?
The study suggests that obese kidney transplant recipients (BMI ≥ 28 kg/m²) require enhanced perioperative monitoring, optimization of immunosuppressive regimens, and individualized fluid management strategies to improve early graft function and reduce hospital stay.
What was the sample size and study design?
This was a retrospective cohort study of 495 kidney transplant recipients from the Second Xiangya Hospital of Central South University between 2019 and 2020. The recipients were divided into four groups based on body mass index, and outcomes were compared using multivariate regression analysis.
What are the limitations of this study?
The study did not include long-term follow-up data, so the impact of body mass index on long-term graft survival could not be assessed. Additionally, the obese group had a small sample size (n=25), which may limit the generalizability of the findings.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.